380 related articles for article (PubMed ID: 29338113)
1. Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study.
Cheung DG; Aizenberg D; Gorbunov V; Hafeez K; Chen CW; Zhang J
J Clin Hypertens (Greenwich); 2018 Jan; 20(1):150-158. PubMed ID: 29338113
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients (≥65 Years) With Systolic Hypertension.
Supasyndh O; Wang J; Hafeez K; Zhang Y; Zhang J; Rakugi H
Am J Hypertens; 2017 Nov; 30(12):1163-1169. PubMed ID: 28992296
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study.
Huo Y; Li W; Webb R; Zhao L; Wang Q; Guo W
J Clin Hypertens (Greenwich); 2019 Jan; 21(1):67-76. PubMed ID: 30536595
[TBL] [Abstract][Full Text] [Related]
4. Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study.
Williams B; Cockcroft JR; Kario K; Zappe DH; Brunel PC; Wang Q; Guo W
Hypertension; 2017 Mar; 69(3):411-420. PubMed ID: 28093466
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study.
Rakugi H; Kario K; Yamaguchi M; Sasajima T; Gotou H; Zhang J
Hypertens Res; 2022 May; 45(5):824-833. PubMed ID: 35058583
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety Comparative of Sacubitril/Valsartan vs. Olmesartan in the Treatment of hypertension: A Meta-analysis of RCTs.
Han Y; Zhou Y; Na J; Li F; Sun Y
Am J Hypertens; 2023 Nov; 36(12):643-650. PubMed ID: 37596996
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Crystalline Valsartan/Sacubitril (LCZ696) Compared With Placebo and Combinations of Free Valsartan and Sacubitril in Patients With Systolic Hypertension: The RATIO Study.
Izzo JL; Zappe DH; Jia Y; Hafeez K; Zhang J
J Cardiovasc Pharmacol; 2017 Jun; 69(6):374-381. PubMed ID: 28338503
[TBL] [Abstract][Full Text] [Related]
8. Different Doses of Sacubitril/Valsartan Compared with Olmesartan in Patients with Essential Hypertension: A Systematic Review and Meta-Analysis.
Almarjan AI; Almarjan SA; Masoud AT
High Blood Press Cardiovasc Prev; 2023 May; 30(3):207-218. PubMed ID: 37017901
[TBL] [Abstract][Full Text] [Related]
9. Twenty-Four-Hour Blood Pressure-Lowering Efficacy of Sacubitril/Valsartan Versus Olmesartan in Japanese Patients With Essential Hypertension Based on Nocturnal Blood Pressure Dipping Status: A Post Hoc Analysis of Data From a Randomized, Double-Blind Multicenter Study.
Kario K; Rakugi H; Yarimizu D; Morita Y; Eguchi S; Iekushi K
J Am Heart Assoc; 2023 Apr; 12(8):e027612. PubMed ID: 37026551
[TBL] [Abstract][Full Text] [Related]
10. Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension.
Supasyndh O; Sun N; Kario K; Hafeez K; Zhang J
Hypertens Res; 2017 May; 40(5):472-476. PubMed ID: 27853163
[TBL] [Abstract][Full Text] [Related]
11. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
Schmieder RE; Wagner F; Mayr M; Delles C; Ott C; Keicher C; Hrabak-Paar M; Heye T; Aichner S; Khder Y; Yates D; Albrecht D; Langenickel T; Freyhardt P; Janka R; Bremerich J
Eur Heart J; 2017 Nov; 38(44):3308-3317. PubMed ID: 29029087
[TBL] [Abstract][Full Text] [Related]
12. Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study).
Chung WB; Ihm SH; Jang SW; Her SH; Park CS; Lee JM; Chang K; Jeon DS; Yoo KD; Seung KB
Drug Des Devel Ther; 2020; 14():347-360. PubMed ID: 32158190
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy.
Wang JG; Yukisada K; Sibulo A; Hafeez K; Jia Y; Zhang J
J Hypertens; 2017 Apr; 35(4):877-885. PubMed ID: 28030431
[TBL] [Abstract][Full Text] [Related]
14. Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan.
Selvaraj S; Claggett BL; Böhm M; Anker SD; Vaduganathan M; Zannad F; Pieske B; Lam CSP; Anand IS; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2020 Apr; 75(14):1644-1656. PubMed ID: 32192799
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study.
Kario K; Sun N; Chiang FT; Supasyndh O; Baek SH; Inubushi-Molessa A; Zhang Y; Gotou H; Lefkowitz M; Zhang J
Hypertension; 2014 Apr; 63(4):698-705. PubMed ID: 24446062
[TBL] [Abstract][Full Text] [Related]
16. Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension.
Wang TD; Tan RS; Lee HY; Ihm SH; Rhee MY; Tomlinson B; Pal P; Yang F; Hirschhorn E; Prescott MF; Hinder M; Langenickel TH
Hypertension; 2017 Jan; 69(1):32-41. PubMed ID: 27849566
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, multinational, phase III study.
Fogari R; Taddei S; Holm-Bentzen M; Baszak J; Melani L; Schumacher K
Clin Drug Investig; 2010; 30(9):581-97. PubMed ID: 20593911
[TBL] [Abstract][Full Text] [Related]
18. The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy.
Giles TD; Oparil S; Ofili EO; Pitt B; Purkayastha D; Hilkert R; Samuel R; Sowers JR
Blood Press Monit; 2011 Apr; 16(2):87-95. PubMed ID: 21386706
[TBL] [Abstract][Full Text] [Related]
19. Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Metabolism in Patients With Obesity and Hypertension.
Engeli S; Stinkens R; Heise T; May M; Goossens GH; Blaak EE; Havekes B; Jax T; Albrecht D; Pal P; Tegtbur U; Haufe S; Langenickel TH; Jordan J
Hypertension; 2018 Jan; 71(1):70-77. PubMed ID: 29180454
[TBL] [Abstract][Full Text] [Related]
20. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
Smith DH; Dubiel R; Jones M
Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
